Incyte Corporation (0J9P.L)
USD 69.2
(0.13%)
USD 69.2
(0.13%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.19 Billion USD | 7.51% |
| 2022 | 2.59 Billion USD | 16.17% |
| 2021 | 2.23 Billion USD | -19.49% |
| 2020 | 2.77 Billion USD | 71.04% |
| 2019 | 1.62 Billion USD | -0.58% |
| 2018 | 1.63 Billion USD | -3.57% |
| 2017 | 1.69 Billion USD | 91.25% |
| 2016 | 885.11 Million USD | 30.91% |
| 2015 | 676.12 Million USD | 31.72% |
| 2014 | 513.29 Million USD | 38.57% |
| 2013 | 370.41 Million USD | 25.25% |
| 2012 | 295.75 Million USD | 24.46% |
| 2011 | 237.63 Million USD | 52.5% |
| 2010 | 155.82 Million USD | 4.56% |
| 2009 | 149.03 Million USD | -8.69% |
| 2008 | 163.2 Million USD | 36.32% |
| 2007 | 119.72 Million USD | 14.56% |
| 2006 | 104.5 Million USD | -3.8% |
| 2005 | 108.63 Million USD | -33.36% |
| 2004 | 162.99 Million USD | 0.35% |
| 2003 | 162.43 Million USD | -18.59% |
| 2002 | 199.52 Million USD | -29.74% |
| 2001 | 283.96 Million USD | -2.62% |
| 2000 | 291.59 Million USD | 39.72% |
| 1999 | 208.7 Million USD | 48.65% |
| 1998 | 140.4 Million USD | 53.61% |
| 1997 | 91.4 Million USD | 68.63% |
| 1996 | 54.2 Million USD | 110.08% |
| 1995 | 25.8 Million USD | 95.45% |
| 1994 | 13.2 Million USD | 725.0% |
| 1993 | 1.6 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 882.37 Million USD | -36.57% |
| 2024 Q1 | 728.53 Million USD | -1.72% |
| 2024 Q2 | 1.42 Billion USD | 96.01% |
| 2023 Q3 | 644.65 Million USD | -5.77% |
| 2023 FY | 2.79 Billion USD | 7.51% |
| 2023 Q4 | 741.29 Million USD | 14.99% |
| 2023 Q1 | 720.88 Million USD | -6.75% |
| 2023 Q2 | 684.1 Million USD | -5.1% |
| 2022 Q1 | 567.69 Million USD | -19.65% |
| 2022 FY | 2.59 Billion USD | 16.17% |
| 2022 Q4 | 773.09 Million USD | 18.52% |
| 2022 Q3 | 652.27 Million USD | 8.17% |
| 2022 Q2 | 603.01 Million USD | 6.22% |
| 2021 Q2 | 522.25 Million USD | 10.84% |
| 2021 Q3 | 534.79 Million USD | 2.4% |
| 2021 Q4 | 706.57 Million USD | 32.12% |
| 2021 FY | 2.23 Billion USD | -19.49% |
| 2021 Q1 | 471.17 Million USD | -19.51% |
| 2020 Q3 | 573.89 Million USD | 37.34% |
| 2020 Q1 | 1.19 Billion USD | 166.91% |
| 2020 Q2 | 417.85 Million USD | -65.14% |
| 2020 FY | 2.77 Billion USD | 71.04% |
| 2020 Q4 | 585.36 Million USD | 2.0% |
| 2019 Q2 | 395.3 Million USD | 0.2% |
| 2019 Q1 | 394.52 Million USD | -4.38% |
| 2019 FY | 1.62 Billion USD | -0.58% |
| 2019 Q3 | 383.94 Million USD | -2.87% |
| 2019 Q4 | 449.04 Million USD | 16.96% |
| 2018 Q3 | 389.04 Million USD | -4.2% |
| 2018 Q4 | 412.59 Million USD | 6.05% |
| 2018 Q1 | 424.6 Million USD | -22.06% |
| 2018 FY | 1.63 Billion USD | -3.57% |
| 2018 Q2 | 406.11 Million USD | -4.35% |
| 2017 Q2 | 291.91 Million USD | -41.05% |
| 2017 FY | 1.69 Billion USD | 91.25% |
| 2017 Q1 | 495.2 Million USD | 92.19% |
| 2017 Q3 | 360.88 Million USD | 23.63% |
| 2017 Q4 | 544.76 Million USD | 50.95% |
| 2016 Q3 | 218.96 Million USD | 17.05% |
| 2016 Q2 | 187.06 Million USD | -15.52% |
| 2016 FY | 885.11 Million USD | 30.91% |
| 2016 Q1 | 221.42 Million USD | 30.94% |
| 2016 Q4 | 257.67 Million USD | 17.68% |
| 2015 Q4 | 169.09 Million USD | -5.89% |
| 2015 Q2 | 164.12 Million USD | 0.54% |
| 2015 FY | 676.12 Million USD | 31.72% |
| 2015 Q3 | 179.67 Million USD | 9.47% |
| 2015 Q1 | 163.23 Million USD | 10.92% |
| 2014 Q1 | 112.55 Million USD | -0.43% |
| 2014 Q3 | 127.98 Million USD | 1.91% |
| 2014 Q2 | 125.58 Million USD | 11.57% |
| 2014 Q4 | 147.16 Million USD | 14.99% |
| 2014 FY | 513.29 Million USD | 38.57% |
| 2013 Q4 | 113.04 Million USD | 15.18% |
| 2013 Q2 | 84.19 Million USD | 12.23% |
| 2013 Q1 | 75.02 Million USD | -10.14% |
| 2013 FY | 370.41 Million USD | 25.25% |
| 2013 Q3 | 98.15 Million USD | 16.57% |
| 2012 Q2 | 71.3 Million USD | 1.35% |
| 2012 Q4 | 83.49 Million USD | 18.26% |
| 2012 Q3 | 70.59 Million USD | -0.99% |
| 2012 Q1 | 70.35 Million USD | -3.66% |
| 2012 FY | 295.75 Million USD | 24.46% |
| 2011 Q1 | 47.79 Million USD | 9.73% |
| 2011 FY | 237.63 Million USD | 52.5% |
| 2011 Q4 | 73.02 Million USD | 24.02% |
| 2011 Q3 | 58.88 Million USD | 1.66% |
| 2011 Q2 | 57.92 Million USD | 21.19% |
| 2010 FY | 155.82 Million USD | 4.56% |
| 2010 Q4 | 43.55 Million USD | 11.9% |
| 2010 Q3 | 38.92 Million USD | 7.47% |
| 2010 Q2 | 36.22 Million USD | -2.41% |
| 2010 Q1 | 37.11 Million USD | -22.81% |
| 2009 Q4 | 48.08 Million USD | 47.95% |
| 2009 FY | 149.03 Million USD | -8.69% |
| 2009 Q1 | 34.91 Million USD | -18.25% |
| 2009 Q2 | 33.52 Million USD | -3.98% |
| 2009 Q3 | 32.5 Million USD | -3.06% |
| 2008 Q1 | 37.3 Million USD | 1.78% |
| 2008 Q4 | 42.71 Million USD | 4.29% |
| 2008 FY | 163.2 Million USD | 36.32% |
| 2008 Q2 | 41.31 Million USD | 10.74% |
| 2008 Q3 | 40.95 Million USD | -0.88% |
| 2007 Q1 | 27.59 Million USD | -7.14% |
| 2007 Q2 | 26.83 Million USD | -2.76% |
| 2007 Q3 | 28.63 Million USD | 6.69% |
| 2007 Q4 | 36.65 Million USD | 28.03% |
| 2007 FY | 119.72 Million USD | 14.56% |
| 2006 Q2 | 26.03 Million USD | -9.07% |
| 2006 Q4 | 29.72 Million USD | 29.15% |
| 2006 Q3 | 23.01 Million USD | -11.61% |
| 2006 Q1 | 28.63 Million USD | 3.66% |
| 2006 FY | 104.5 Million USD | -3.8% |
| 2005 Q1 | 20.9 Million USD | -36.72% |
| 2005 Q4 | 27.62 Million USD | -9.03% |
| 2005 Q2 | 29.73 Million USD | 42.22% |
| 2005 Q3 | 30.36 Million USD | 2.12% |
| 2005 FY | 108.63 Million USD | -33.36% |
| 2004 FY | 162.99 Million USD | 0.35% |
| 2004 Q1 | 40.11 Million USD | -17.7% |
| 2004 Q2 | 66.1 Million USD | 64.78% |
| 2004 Q3 | 23.73 Million USD | -64.1% |
| 2004 Q4 | 33.04 Million USD | 39.22% |
| 2003 Q2 | 37.56 Million USD | -2.85% |
| 2003 Q4 | 48.74 Million USD | 31.15% |
| 2003 Q3 | 37.16 Million USD | -1.05% |
| 2003 Q1 | 38.66 Million USD | -3.14% |
| 2003 FY | 162.43 Million USD | -18.59% |
| 2002 Q4 | 39.91 Million USD | -33.31% |
| 2002 Q2 | 51.83 Million USD | 8.19% |
| 2002 FY | 199.52 Million USD | -29.74% |
| 2002 Q3 | 59.85 Million USD | 15.47% |
| 2002 Q1 | 47.91 Million USD | -30.71% |
| 2001 Q3 | 68.54 Million USD | -7.05% |
| 2001 Q2 | 73.74 Million USD | 1.69% |
| 2001 FY | 283.96 Million USD | -2.62% |
| 2001 Q4 | 69.14 Million USD | 0.88% |
| 2001 Q1 | 72.52 Million USD | -10.63% |
| 2000 Q3 | 77.36 Million USD | 12.41% |
| 2000 Q2 | 68.82 Million USD | 7.08% |
| 2000 FY | 291.59 Million USD | 39.72% |
| 2000 Q1 | 64.26 Million USD | 7.29% |
| 2000 Q4 | 81.14 Million USD | 4.89% |
| 1999 Q2 | 52 Million USD | 15.56% |
| 1999 Q3 | 51.8 Million USD | -0.38% |
| 1999 Q4 | 59.9 Million USD | 15.64% |
| 1999 Q1 | 45 Million USD | 8.17% |
| 1999 FY | 208.7 Million USD | 48.65% |
| 1998 Q4 | 41.6 Million USD | 15.56% |
| 1998 Q2 | 32.8 Million USD | 9.33% |
| 1998 FY | 140.4 Million USD | 53.61% |
| 1998 Q1 | 30 Million USD | 13.64% |
| 1998 Q3 | 36 Million USD | 9.76% |
| 1997 Q3 | 23.5 Million USD | 6.33% |
| 1997 FY | 91.4 Million USD | 68.63% |
| 1997 Q4 | 26.4 Million USD | 12.34% |
| 1997 Q1 | 19.5 Million USD | 17.47% |
| 1997 Q2 | 22.1 Million USD | 13.33% |
| 1996 Q1 | 9.4 Million USD | 13.25% |
| 1996 Q3 | 15.6 Million USD | 40.54% |
| 1996 FY | 54.2 Million USD | 110.08% |
| 1996 Q4 | 16.6 Million USD | 6.41% |
| 1996 Q2 | 11.1 Million USD | 18.09% |
| 1995 Q3 | 6.6 Million USD | 15.79% |
| 1995 Q2 | 5.7 Million USD | 39.02% |
| 1995 Q4 | 8.3 Million USD | 25.76% |
| 1995 Q1 | 4.1 Million USD | -12.77% |
| 1995 FY | 25.8 Million USD | 95.45% |
| 1994 Q1 | 2.3 Million USD | 666.67% |
| 1994 Q2 | 1.1 Million USD | -52.17% |
| 1994 FY | 13.2 Million USD | 725.0% |
| 1994 Q4 | 4.7 Million USD | 38.24% |
| 1994 Q3 | 3.4 Million USD | 209.09% |
| 1993 FY | 1.6 Million USD | 0.0% |
| 1993 Q3 | 400 Thousand USD | 0.0% |
| 1993 Q4 | 300 Thousand USD | -25.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -381.389% |
| Dynavax Technologies Corporation | 219.14 Million USD | -443.245% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -125.042% |
| Perrigo Company plc | 1.52 Billion USD | 22.114% |
| Illumina, Inc. | 3.81 Billion USD | 68.778% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 88.39% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -163.972% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 97.068% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 42.012% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -886.677% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 57.713% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2565.267% |
| Waters Corporation | 943.51 Million USD | -26.176% |
| Biogen Inc. | 5.2 Billion USD | 77.127% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -420.594% |
| Evolus, Inc. | 189.75 Million USD | -527.372% |
| Adicet Bio, Inc. | 152.03 Million USD | -683.025% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -735.652% |
| bluebird bio, Inc. | 240.23 Million USD | -395.561% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -337.848% |
| FibroGen, Inc. | 398.11 Million USD | -199.034% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 43.712% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -8458.776% |
| Homology Medicines, Inc. | 9.87 Million USD | -11955.646% |
| Geron Corporation | 70.44 Million USD | -1590.06% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 33.864% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -178.38% |
| Myriad Genetics, Inc. | 600.1 Million USD | -98.383% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1080.73% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -115.839% |
| Zoetis Inc. | 2.76 Billion USD | 56.944% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -2354.528% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -9.281% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 31.827% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 75.068% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -2940.623% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -52.708% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -331.819% |
| Verastem, Inc. | 92.08 Million USD | -1192.836% |
| Nektar Therapeutics | 190.9 Million USD | -523.613% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -149.915% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -9705.576% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 12.516% |
| OPKO Health, Inc. | 574.68 Million USD | -107.156% |
| Exelixis, Inc. | 1.58 Billion USD | 24.974% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 25.431% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -222.967% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -2035.187% |
| uniQure N.V. | 285.08 Million USD | -317.592% |
| Imunon, Inc. | 21.03 Million USD | -5560.821% |
| Blueprint Medicines Corporation | 722.86 Million USD | -64.692% |
| Insmed Incorporated | 949.26 Million USD | -25.413% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -297.736% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -191.213% |
| TG Therapeutics, Inc. | 198.47 Million USD | -499.821% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -14.032% |